Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

Cited by (7,499)

Items 801–900 of 7,499

1. The Evidence Base for Tight Blood Pressure Control in the Management of Type 2 Diabetes Mellitus
   Vincenza T. Snow, Kevin B. Weiss, Christel Mottur-Pilson · 2003 · Annals of Internal Medicine
2. Improving the residual risk of renal and cardiovascular outcomes in diabetic kidney disease: A review of pathophysiology, mechanisms, and evidence from recent trials
   Chaudhuri, Ajay, Ghanim, Husam, Arora, Pradeep · 2022 · Diabetes, Obesity and Metabolism
3. Type 2 Diabetes
   Sandeep S. Vijan · 2015 · Annals of Internal Medicine
4. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta‐analysis
   Douglas L. Jennings, James S. Kalus, Craig Ian Coleman, C. Manierski, Jerry Yee · 2007 · Diabetic Medicine
5. Endoplasmic reticulum stress drives proteinuria-induced kidney lesions via Lipocalin 2
   Khalil El Karoui, Amandine Viau, Olivier Dellis, Alessia Bagattin, Clément Nguyen, William Baron, Martine Burtin, Mélanie Broueilh, Laurence Heidet, Géraldine Mollet et al. · 2016 · Nature Communications
6. Management of hyperkalemia in patients with kidney disease: a position paper endorsed by the Italian Society of Nephrology
   Stefano Bianchi, Filippo Aucella, Luca De Nicola, Simonetta Genovesi, Ernesto Paoletti, Giuseppe Regolisti · 2019 · Journal of Nephrology
7. Diabetic kidney disease: new clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on “The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function”
   the Italian Diabetes Society and the Italian Society of Nephrology, Giuseppe Pugliese, Giuseppe Penno, Andrea Natali, Federica Barutta, Salvatore Di Paolo, Gianpaolo Reboldi, Loreto Gesualdo, Luca De Nicola · 2019 · Journal of Nephrology
8. Rationale and Design for the Blood Pressure Intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial
   Cushman, William C., Grimm, Richard H., Cutler, Jeffrey A., Evans, Gregory W., Capes, Sarah, Corson, Marshall A., Sadler, Laurie S., Alderman, Michael H., Peterson, Kevin, Bertoni, Alain et al. · 2007 · The American Journal of Cardiology
9. Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection
   Michos, Erin D., Bakris, George L., Rodbard, Helena W., Tuttle, Katherine R. · 2023 · American Journal of Preventive Cardiology
10. Combination Therapy with the Advanced Glycation End Product Cross-Link Breaker, Alagebrium, and Angiotensin Converting Enzyme Inhibitors in Diabetes: Synergy or Redundancy?
    Coughlan, Melinda T., Thallas-Bonke, Vicki, Pete, Josefa, Long, David M., Gasser, Anna, Tong, David C. K., Arnstein, Maryann, Thorpe, Suzanne R., Cooper, Mark E., Forbes, Josephine M. · 2007 · Endocrinology
11. Income‐Related Differences in the Use of Evidence‐Based Therapies in Older Persons with Diabetes Mellitus in For‐Profit Managed Care
    Arleen F. Brown, Amy G. Gross, Peter R. Gutierrez, Luohua Jiang, Martin F. Shapiro, Carol M. Mangione · 2003 · Journal of the American Geriatrics Society
12. Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials
    Frank A. Holtkamp, Dick de Zeeuw, P. A. de Graeff, Gozewijn Dirk Laverman, Tomás Berl, Giuseppe Remuzzi, David Packham, Julia Breyer Lewis, H.‐H. Parving, Hiddo J.L. Heerspink · 2011 · European Heart Journal
13. Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes
    Elena Gagliardini, Daniela Corna, Carla Zoja, Fabio Sangalli, Fabiola Carrara, M.G. De Rossi, Sara Conti, Daniela Rottoli, Lorena Longaretti, Andrea Remuzzi et al. · 2009 · American Journal of Physiology-Renal Physiology
14. Prevention of Microvascular Complications of Diabetes
    Winston Crasto, Vinod Patel, Melanie Jane Davies, Kamlesh K. Khunti · 2021 · Endocrinology and Metabolism Clinics of North America
15. Epidemiology, Pathophysiology, Prognosis, and Treatment of Systolic and Diastolic Heart Failure
    Wilbert S. Aronow · 2006 · Cardiology in Review
16. Balancing Calcium Signals through TRPC5 and TRPC6 in Podocytes
    Anna Greka, Peter H. Mundel · 2011 · Journal of the American Society of Nephrology
17. Rationale—Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney disease
    T.-Christian H. Mix, Robert M. Brenner, Mark Emmanuel Cooper, Dick de Zeeuw, Peter T. Ivanovich, Andrew S. Levey, Janet B. McGill, John J.V. McMurray, Patrick S. Parfrey, Hans‐Henrik Parving et al. · 2005 · American Heart Journal
18. Blood Pressure Components and the Risk for End-Stage Renal Disease and Death in Chronic Kidney Disease
    Rajiv Agarwal · 2009 · Clinical Journal of the American Society of Nephrology
19. Effect of low-protein diet on kidney function in diabetic nephropathy: meta-analysis of randomised controlled trials
    Uru Nezu, Hiroshi Kamiyama, Yoshinobu Kondo, Mio Sakuma, Takeshi Morimoto, Shinichiro Ueda · 2013 · BMJ Open
20. Role of Impaired Nutrient and Oxygen Deprivation Signaling and Deficient Autophagic Flux in Diabetic CKD Development: Implications for Understanding the Effects of Sodium-Glucose Cotransporter 2-Inhibitors
    Milton Packer · 2020 · Journal of the American Society of Nephrology
21. Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape
    Christian W. Mende · 2021 · Advances in Therapy
22. Evidence-based Practice Guideline for the Treatment of CKD
    2009 · Clinical and Experimental Nephrology
23. 9. Microvascular Complications and Foot Care
    American Diabetes Association · 2014 · Diabetes Care
24. 2023 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association
    Jong Han Choi, Kyung Ae Lee, Joon Ho Moon, Suk Chon, Dae Jung Kim, Hyun Jin Kim, Nan Hee Kim, Ji A Seo, Mee Kyoung Kim, Jeong Hyun Lim et al. · 2023 · Diabetes & Metabolism Journal
25. Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial
    PK Judge, Natalie Staplin, KJ Mayne, Christoph Wanner, JB Green, Sibylle Jenny Hauske, Jonathan Emberson, David Preiss, SYA Ng, AJ Roddick et al. · 2023 · The Lancet Diabetes & Endocrinology
26. Diuretic and Enhanced Sodium Restriction Results in Improved Antiproteinuric Response to RAS Blocking Agents
    Vincent L.M. Esnault, A. Ekhlas, Catherine Delcroix, Moutel Mg, Jean‐Michel Nguyen · 2004 · Journal of the American Society of Nephrology
27. Diabetes, hypertension, and cardiovascular derangements: Pathophysiology and management
    El-Atat, Fadi, McFarlane, Samy I., Sowers, James R. · 2004 · Current Hypertension Reports
28. Current therapeutic interventions in the glycation pathway: evidence from clinical studies
    Lian Engelen, Coen D.A. Stehouwer, Caspar Schalkwijk · 2012 · Diabetes Obesity and Metabolism
29. CKD in Hispanics: Baseline Characteristics From the CRIC (Chronic Renal Insufficiency Cohort) and Hispanic-CRIC Studies
    Michael J. Fischer, Alan S. Go, Claudia M. Lora, Lynn Ackerson, Janet Cohan, John W. Kusek, Alejandro Mercado, AKINLOLU O. OJO, Ana Catherine Ricardo, Leigh Rosen et al. · 2011 · American Journal of Kidney Diseases
30. Additive Antiproteinuric Effect of Pentoxifylline in Patients with Type 2 Diabetes under Angiotensin II Receptor Blockade
    Juan F. Navarro‐González, Carmen Mora, Mercedes Muros, Javier Garcı́a Garcı́a · 2005 · Journal of the American Society of Nephrology
31. Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre trial
    Morten Kofod Lindhardt, Frederik Persson, Gemma E. Currie, Claudia Pontillo, Joachim Beige, Christian Delles, Heiko E. von der Leyen, Harald Mischak, Gerjan J Navis, Marina Noutsou et al. · 2016 · BMJ Open
32. Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease
    Carlos Maria Ferrario, Adam E. Mullick · 2017 · Pharmacological Research
33. Medication Safety Principles and Practice in CKD
    Chanel F. Whittaker, Margaret A. Miklich, Roshni S. Patel, Jeffrey Craig Fink · 2018 · Clinical Journal of the American Society of Nephrology
34. Documento de información y consenso para la detección y manejo de la enfermedad renal crónica
    Rafael García Maset, Jordi Bover, J. Segura, Marian Goicoechea Diezhandino, Jesús Cebollada del Hoyo, Javier Escalada San Martín, Lorenzo Fácila, Javier Gamarra, José Antonio García‐Donaire, Lisardo García Matarin et al. · 2021 · Nefrología
35. Endoplasmic reticulum stress-triggered ferroptosis via the XBP1-Hrd1-Nrf2 pathway induces EMT progression in diabetic nephropathy.
    Zi‐Jun Liu, Ping Nan, Yihui Gong, Ling Tian, Zheng Yin, Zhongming Wu · 2023 · Biomedicine & Pharmacotherapy
36. Long-term renal consequences of hypertension for normal and diseased kidneys
    ANIL K. BIDANI, Karen A. Griffin · 2002 · Current Opinion in Nephrology & Hypertension
37. Heart Rate and Blood Pressure: Any Possible Implications for Management of Hypertension?
    Scott A. Reule, Paul E. Drawz · 2012 · Current Hypertension Reports
38. Treatment of idiopathic membranous nephropathy
    Julia M. Hofstra, Fernando Custodio Fervenza, Jack F.M. Wetzels · 2013 · Nature Reviews Nephrology
39. Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits
    Jens Oellgaard, Peter Gæde, Peter R Rossing, Frederik Persson, Hans‐Henrik Parving, Oluf Borbye Pedersen · 2017 · Kidney International
40. Cumulative Kidney Complication Risk by 50 Years of Type 1 Diabetes: The Effects of Sex, Age, and Calendar Year at Onset
    Tina Costacou, Trevor John Orchard · 2017 · Diabetes Care
41. Therapeutic Advances in Diabetic Nephropathy
    Hanny Sawaf, George Thomas, Jonathan J. Taliercio, Georges Nakhoul, Tushar J. Vachharajani, Ali Mehdi · 2022 · Journal of Clinical Medicine
42. Blockade of the renin–angiotensin–aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes
    Michel Burnier, Anne Zanchi · 2005 · Journal of Hypertension
43. Glomerular hemodynamics and the renin-angiotensin system in patients with type 1 diabetes mellitus
    Norman K. Hollenberg, Deborah A. Price, Naomi D.L. Fisher, Maria Cecilia Lansang, Bruce A. Perkins, Michael S. Gordon, Gordon H. Williams, Lori M. Laffel · 2003 · Kidney International
44. Latin American guidelines on hypertension*
    Ramiro Ariel Sanchez, Miryam Ayala, Hugo P. Baglivo, Carlos Velazquez, Guillermo Burlando, Oswaldo Kohlmann, Jorge Jimenez, Patricio A López-Jaramillo, Ayrton Brandao, Gloría Valdés et al. · 2009 · Journal of Hypertension
45. Role of podocyte slit diaphragm as a filtration barrier (Review Article)
    Hiroshi Kawachi, Naoko Miyauchi, Koichi Suzuki, Gi Dong Han, Michiaki Orikasa, Fujio Shimizu · 2006 · Nephrology
46. Trends in the prevalence of chronic kidney disease and its risk factors in a general Japanese population: the Hisayama Study.
    Masaharu Nagata, T. Ninomiya, Y. Doi, K. Yonemoto, M. Kubo, J. Hata, K. Tsuruya, M. Iida, Y. Kiyohara · 2010 · Nephrology, Dialysis and Transplantation
47. Benefits and Safety of Long-Term Fenofibrate Therapy in People With Type 2 Diabetes and Renal Impairment
    Ting, Ru-Dee, Keech, Anthony C., Drury, Paul L., Donoghoe, Mark W., Hedley, John, Jenkins, Alicia J., Davis, Timothy M.E., Lehto, Seppo, Celermajer, David, Simes, R. John et al. · 2012 · Diabetes Care
48. Effects of ACE-Inhibitors and Angiotensin Receptor Blockers on Inflammation
    Domenico Di Raimondo, Antonino Tuttolomondo, Carmelo Buttà, S. Miceli, Giuseppe Licata, Antonio Ventura Pinto · 2012 · Current Pharmaceutical Design
49. Slowing Nephropathy Progression
    George L. Bakris · 2008 · Clinical Journal of the American Society of Nephrology
50. Clinical Features and Outcomes of IgA Nephropathy with Nephrotic Syndrome
    Jwa-Kyung Kim, Jeong Ho Kim, Sang Choel Lee, Ea Wha Kang, Tae Ik Chang, Sung Jin Moon, Soo Young Yoon, Tae‐Hyun Yoo, Shin‐Wook Kang, Kyu Hun Choi et al. · 2012 · Clinical Journal of the American Society of Nephrology
51. Combination therapy for kidney disease in people with diabetes mellitus
    van Raalte, Daniël H., Bjornstad, Petter, Cherney, David Z. I., de Boer, Ian H., Fioretto, Paola, Gordin, Daniel, Persson, Frederik, Rosas, Sylvia E., Rossing, Peter, Schaub, Jennifer A. et al. · 2024 · Nature Reviews Nephrology
52. The past, present and future of renin–angiotensin aldosterone system inhibition
    Robert John Mentz, George L. Bakris, Bernard Waeber, John J.V. McMurray, Mihai Gheorghiade, Luis Miguel Ruilope, Aldo Pietro Maggioni, Karl B Swedberg, Ileana L. Piña, Mona Fiuzat et al. · 2012 · International Journal of Cardiology
53. Benefits of dietary sodium restriction in the management of chronic kidney disease
    Jan A. Krikken, Gozewijn Dirk Laverman, Gerjan J Navis · 2009 · Current Opinion in Nephrology & Hypertension
54. Effects of Intensive Systolic Blood Pressure Control on Kidney and Cardiovascular Outcomes in Persons Without Kidney Disease
    Srinivasan Beddhu, Michael V. Rocco, Robert D. Toto, Timothy E. Craven, Tom Greene, Udayan Y. Bhatt, Alfred K. Cheung, Debbie L. Cohen, Barry I. Freedman, Amret T. Hawfield et al. · 2017 · Annals of Internal Medicine
55. Global case studies for chronic kidney disease/end-stage kidney disease care
    Chih‐Wei Yang, David C.H. Harris, Valérie A. Luyckx et al. · 2020 · Kidney International Supplements
56. Arjunolic acid: A new multifunctional therapeutic promise of alternative medicine
    Jyotirmoy Ghosh, Parames Chandra Sil · 2013 · Biochimie
57. Comparison of the Novel Angiotensin II Receptor Blocker Azilsartan Medoxomil vs Valsartan by Ambulatory Blood Pressure Monitoring
    Domenic A. Sica, William B. White, Michael A. Weber, George L. Bakris, Alfonso Pérez, Charlie Cao, Alison Handley, Stuart Kupfer · 2011 · Journal of Clinical Hypertension
58. Should the sympathetic nervous system be a target to improve cardiometabolic risk in obesity?
    Élisabeth Lambert, Nora E. Straznicky, John B. Dixon, Gavin William Lambert · 2015 · American Journal of Physiology-Heart and Circulatory Physiology
59. A Novel Role for Type 1 Angiotensin Receptors on T Lymphocytes to Limit Target Organ Damage in Hypertension
    Jian-dong Zhang, Mehul B. Patel, Young-Soo Song, Robert Griffiths, James L. Burchette, Phillip Ruiz, Matthew A. Sparks, Ming Yan, David N. Howell, José A. Gómez et al. · 2012 · Circulation Research
60. Resistive index predicts renal prognosis in chronic kidney disease
    T. Sugiura, Akira Wada · 2009 · Nephrology Dialysis Transplantation
61. The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
    Keizo Kanasaki · 2018 · Clinical Science
62. Of the renin-angiotensin system and reactive oxygen speciesType 2 diabetes and angiotensin II inhibition
    L LEITER, Richard Z. Lewanczuk · 2005 · American Journal of Hypertension
63. The renal patient with coronary artery disease
    Rajiv Gupta, Yochai Birnbaum, Barry F. Uretsky · 2004 · Journal of the American College of Cardiology
64. Intervention strategies to prevent pathogenetic effects of glycated albumin
    Margo Panush Cohen · 2003 · Archives of Biochemistry and Biophysics
65. RAS inhibition in hypertension
    Ibrahim, M Mohsen · 2006 · Journal of Human Hypertension
66. Quality of care and mortality are worse in chronic kidney disease patients living in remote areas
    Diana Rucker, Brenda R. Hemmelgarn, Meng Lin, Braden Manns, Scott W Klarenbach, Bharati Ayyalasomayajula, Matthew Thomas James, Aminu K. Bello, Deb Gordon, Kailash K Jindal et al. · 2010 · Kidney International
67. Early Detection of CKD: Implications for Low-Income, Middle-Income, and High-Income Countries
    Marcello A. Tonelli, James Arthur Dickinson · 2020 · Journal of the American Society of Nephrology
68. Albuminuria in Cardiovascular, Kidney, and Metabolic Disorders: A State-of-the-Art Review
    Sophie E. Claudel, Ashish Verma · 2025 · Circulation
69. Peripheral artery disease and CKD: a focus on peripheral artery disease as a critical component of CKD care.
    P. Garimella, P. Hart, A. O'Hare, S. Deloach, C. Herzog, A. Hirsch · 2012 · American Journal of Kidney Diseases
70. Intravenous Administration of Hepatocyte Growth Factor Gene Ameliorates Diabetic Nephropathy in Mice
    Chunsun Dai, Junwei Yang, Sheldon Bastacky · 2004 · Journal of the American Society of Nephrology
71. Renal Lesions Predict Progression of Diabetic Nephropathy in Type 1 Diabetes
    Maria Luiza Caramori, Alicia Parks, Michael S. Mauer · 2013 · Journal of the American Society of Nephrology
72. Cardiovascular disease in patients with chronic kidney disease
    Alastair J Hutchison · 2009 · Vascular Health and Risk Management
73. Clinical Manifestation and Natural History of Diabetic Nephropathy
    Eberhard Ritz, Xiaoxi Zeng, Ivan Rychlík · 2011 · Contributions to nephrology
74. The Effect of Pentoxifylline on Proteinuria in Diabetic Kidney Disease: A Meta-analysis
    Brendan B. McCormick, A Sydor, Ayub Akbari · 2008 · American Journal of Kidney Diseases
75. Calcitriol, calcidiol, parathyroid hormone, and fibroblast growth factor‐23 interactions in chronic kidney disease
    Joao Felipe de Brito Galvão, Larry Allen Nagode, Patricia A. Schenck, Dennis J. Chew · 2013 · Journal of Veterinary Emergency and Critical Care
76. Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I–II essential hypertension: a randomized, double-blind clinical study
    Hiromi Rakugi, Kazuaki Enya, Kenkichi Sugiura, Yoshinori Ikeda · 2012 · Hypertension Research
77. Ramipril versus placebo in kidney transplant patients with proteinuria: a multicentre, double-blind, randomised controlled trial
    Greg A. Knoll, Dean A. Fergusson, Michaël Chassé, Paul C. Hébert, George A. Wells, Lee Anne Tibbles, Darin J. Treleaven, David C Holland, Christine A. White, Norman Muirhead et al. · 2015 · The Lancet Diabetes & Endocrinology
78. Endoplasmic reticulum protein TXNDC5 promotes renal fibrosis by enforcing TGF-β signaling in kidney fibroblasts
    Yen‐Ting Chen, Pei-Yu Jhao, Chen‐Ting Hung, Yueh‐Feng Wu, Sung‐Jan Lin, Wen‐Chih Chiang, Shuei‐Liong Lin, Kai‐Chien Yang · 2021 · Journal of Clinical Investigation
79. The Burden of Uncontrolled Hypertension: Morbidity and Mortality Associated With Disease Progression
    William C. Cushman · 2003 · Journal of Clinical Hypertension
80. Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor γ
    Ikuyo Imayama, Toshihiro Ichiki, Keita Inanaga, H OHTSUBO, K FUKUYAMA, H ONO, Yasuko Hashiguchi, Kenji Sunagawa · 2006 · Cardiovascular Research
81. Recommendations for special populations: diabetes mellitus and the metabolic syndrome
    James R. Sowers · 2003 · American Journal of Hypertension
82. Uric Acid as a Mediator of Diabetic Nephropathy
    Diana I. Jalal, David M. Maahs, Peter Hambak Hovind, Takahiko Nakagawa · 2011 · Seminars in Nephrology
83. Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: A post hoc analysis of RENAAL
    Dick de Zeeuw, Denise R Ramjit, Z. Zhang, Artur Beltrame Ribeiro, Kiyoshi Kurokawa, James Phillip Lash, Juliana C.N. Chan, Giuseppe Remuzzi, Barry Morton Brenner, S. Shahinfar · 2006 · Kidney International
84. Decrease in Urinary Albumin Excretion Associated With the Normalization of Nocturnal Blood Pressure in Hypertensive Subjects
    Ramón C. Hermida, Carlos Calvo, Diana E. Ayala, José Enrique López · 2005 · Hypertension
85. Strategies for initial management of hypertension
    Rajeev Gupta, Soneil Guptha · 2010 · The Indian Journal of Medical Research
86. Current Guidelines for Using Angiotensin-Converting Enzyme Inhibitors and Angiotensin II–Receptor Antagonists in Chronic Kidney Disease: Is the Evidence Base Relevant to Older Adults?
    Ann M. O’Hare, James S. Kaufman, Kenneth E. Covinsky, C. Seth Landefeld, Lynne V. McFarland, Eric Berg Larson · 2009 · Annals of Internal Medicine
87. Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS)
    A. Sinclair, Gerald B. Appel, Mary Anne Dooley · 2007 · Lupus
88. Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy
    Justyna Siwy, Joost Peter Schanstra, Àngel Argilés, Stephan J. L. Bakker, Joachim Beige, Petr Bouček, Korbinian Brand, Christian Delles, Flore Duranton, Beatriz Fernández‐Fernández et al. · 2014 · Nephrology Dialysis Transplantation
89. Diabetic nephropathy: where are we on the journey from pathophysiology to treatment?
    Hugh Gallagher, Rebecca Suckling · 2016 · Diabetes Obesity and Metabolism
90. Increased Angiotensin II Sensitivity Contributes to Microvascular Dysfunction in Women Who Have Had Preeclampsia
    Anna E. Stanhewicz, Sandeep Jandu, Lakshmi Santhanam, Lacy M. Alexander · 2017 · Hypertension
91. DNA-Encoded Library-Derived DDR1 Inhibitor Prevents Fibrosis and Renal Function Loss in a Genetic Mouse Model of Alport Syndrome
    Hans Georg Richter, Alexander Lee Satz, Marc Bedoucha, Bernd Buettelmann, Ann C. Petersen, Anja Harmeier, Ricardo Hermosilla, Remo Hochstrasser, Dominique Burger, Bernard Gsell et al. · 2018 · ACS Chemical Biology
92. Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials
    Ausilia Maione, Sankar Dass Navaneethan, Giusi Graziano, Ruth L. Mitchell, David Wayne Johnson, Johannes F.E. Mann, P. Gao, Jonathan C. Craig, Gianni Tognoni, Vlado Perkovic et al. · 2011 · Nephrology Dialysis Transplantation
93. Role of oxidative stress in diabetic nephropathy
    Nina Vasavada, Rajiv Agarwal · 2005 · Advances in Chronic Kidney Disease
94. Screening Adults for Type 2 Diabetes: A Review of the Evidence for the U.S. Preventive Services Task Force
    Russell Harris, Katrina E Donahue, Saif S. Rathore, Paul Frame, Steven H. Woolf, Kathleen N Lohr · 2003 · Annals of Internal Medicine
95. Antifibrotic, nephroprotective potential of ACE inhibitor vs AT1 antagonist in a murine model of renal fibrosis
    Oliver Groß, Eckhard Schulze-Lohoff, Marie-Louise Koepke, Bogdan Beirowski, Klaus Addicks, Wilhelm Bloch, Neil R. Smyth, M. Weber · 2004 · Nephrology Dialysis Transplantation
96. Ameliorating Hypertension and Insulin Resistance in Subjects at Increased Cardiovascular Risk
    Piero Luigi Ruggenenti, Dario Cattaneo, Giacomina Loriga, Franca Ledda, Nicola Motterlini, Giulia Gherardi, Silvia Orisio, Giuseppe Remuzzi · 2009 · Hypertension
97. Autophagy: A Novel Therapeutic Target for Diabetic Nephropathy
    Shinji Kume, Daisuke Koya · 2015 · Diabetes & Metabolism Journal
98. Activation of the renin–angiotensin system within podocytes in diabetes
    Tae‐Hyun Yoo, J.-J. Li, Jae‐Jin Kim, D.-S. Jung, S.-J. Kwak, Dong‐Ryeol Ryu, Hoon Young Choi, Jin Sung Kim, H.J. Kim, Seung Hyeok Han et al. · 2007 · Kidney International
99. Comparison of different therapeutic strategies in hypertension
    Jean‐Jacques Mourad, Bernard Waeber, Fa ez Zannad, Maurice Laville, G. Duru, Michel Andr jak · 2004 · Journal of Hypertension
100. Extent and Management of Cardiovascular Risk Factors in Patients With Type 2 Diabetes and Serious Mental Illness
     Julie A. Kreyenbuhl, Faith Dickerson, Deborah R. Medoff, Clayton H. Brown, Richard W. Goldberg, Lijuan Fang, Karen A. Wohlheiter, Leena P. Mittal, Lisa B. Dixon · 2006 · The Journal of Nervous and Mental Disease